Recent Business Highlights
Addressing unmet needs
in Derma and Neurology
Commercial Updates
⚫ First set of launches Zembrace TM and Sernivo™ ramping
up well, continue to focus on accelerating the commercial
business' path to profitability
•
Promius Pharma recognized as an emerging R&D driven
commercial organization in the neurology and
dermatology communities
R&D Updates
⚫ Filed the NDA for migraine candidate DFN-02
•
Developing robust R&D Pipeline - Three assets in Phase
Ill and Three assets in Phase II respectively
BD Updates
•
Out-licensing of DFD-06, a topical high potency steroid,
to Encore Dermatology
• Global License & Commercialization Agreement for Phase
III Clinical Trial Candidate (DFA 02) for Mitigation of
Surgical Site Infections with CHD Biosciences
14View entire presentation